Conclusion reached: This multicenter, retrospective, cross-sectional study covers the widespread use of psychopharmacotherapeutical options for MDD assessed in tertiary psychiatric treatment centers in Europe.
Abstract

Purpose:
To explore antidepressant effect on the microstructure of brain white matter integrity by diffusion tensor imaging in patients with first-episode major depressive disorder (MDD). Method: In this prospective study, we recruited 32 first-episode patients who met the criteria of the Fourth Edition of Diagnostic and Statistical Manual of Mental Disorders of MDD and 35 age-and sex-matched healthy controls. Brain diffusion tensor imaging was used to determine fractional anisotropy (FA) in preselected white matter regions before and after the patients received a 12-week regimen of sertraline. The severity of depression was evaluated using the 17-item Hamilton Depression Rating Scale (HDRS). Results: Only 11 patients (34.38%) received post-treatment MRI exam. Patients with MDD displayed lower baseline FA values predominantly in bilateral upper frontal white matter at 10mm above the anterior commissure -posterior commissure (AC-PC) plane than healthy controls. The correlation between baseline HDRS scores and FA values was inversely significant in left lower frontal white matter at 10mm below the AC-PC plane (r= -0.359, p=0.043). After treatment, FA values were significantly increased in bilateral upper frontal white matter at 10mm above the AC-PC plane. The differences of FA values in left and right upper frontal white matter at 10mm above the AC-PC plane after treatment remained significant (effect sizes 0.45, 0.54 respectively) even after an intention-to-treat analysis. Conclusion: Antidepressants administered for 12 weeks to firstepisode MDD patients increase FA values. White matter microstructure subnormalities may develop early in the course of illness.
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No Abstract Background: The Phospholipase gene polymorphism is one factor that may influence the treatment outcome of depression. In this trial, the subjects divided into two groups, based on whether they had the PLA2 gene or Non-PLA2 gene, and then underwent treatment with mirtazapine. The purpose of the trial was to determine if the treatment outcome differed between the two groups. Methods: Patients fulfilled the criteria for major depression of the Structured Clinical Interview for the DSM-5 recruited from the psychiatric outpatient clinic at a teaching hospital in southern Taiwan. Chromosomes from the white blood cellular nucleus of venous blood were withdrawn to undergo polymerase chain reaction (PCR). MAOA gene promoters larger than or equal to 4kb were considered long forms, and those smaller than or equal to 3.5kb were regarded as short forms. All patients administered the antidepressant mirtazapine. Both before and after treatment, weekly evaluations using the Hamilton's Depression Rating Scale (HDRS) were made, for a total of four times. Results: 70 volunteers were enrolled and 56 subjects of them completed at least the second evaluation (28 males, 42 females), with 33 in the PLA2 group, and 37 in the Non-PLA2 group. 39 subjects completed the third evaluation, 34 completed the fourth. 14 subjects who completed the first evaluation only withdrew from the trial; this group included 9 subjects with the PLA2 group and 5 with the Non-PLA2 form. The post-treatment HDRS evaluation scores were lower than previous evaluations, but not reach statistical significance (p>0.05). The HDRS scores for subjects who had taken a higher dose were comparatively higher, and reached statistical significance (z=2.17, p=0.03). Conclusion: There was no difference in mirtazapine treatment outcomes between subjects with PLA2 and Non-PLA2 gene. Whether or not this was due to the side effects of the treatment is worthy of further investigation. Previous studies have shown that atypical antipsychotic (AAP) augmentation is effective for treatment-resistant and severe major depressive disorder (MDD). Most treatment guidelines recommend AAP augmentation for treatment of non-or partial-responders to antidepressants (ADs); AAP augmentation is also effective for more severe depression. The effects of ADs usually appear several weeks after initiation of treatment, and AAP augmentation can advance therapeutic responses in some patients. In this study, we performed a naturalistic, retrospective trial to compare early response and remission rates between AD treatment and AAP augmentation in real-life clinical practice. Methods: A retrospective chart review of patients with MDD without psychotic features and starting treatment for a new major depressive episode was conducted between January 2011 and July 2011. Patients treated with mood stabilizers, conventional antipsychotics, psychostimulants or thyroid hormone augmentation were excluded. Hamilton Depression Rating Scale 17-item (HDRS-17) scores were collected at baseline, 2 weeks and 8 ± 1 weeks after treatment. Response was defined as a ≥50% reduction from baseline HDRS-17 scores; remission was a score of ≤7. Results: Of 82 patients included, 31 were in the AD group and 51 were in the AAP augmentation group. At 8 weeks, the AD group was taking 1.26 ± 0.51 types of ADs and the AAP augmentation group 1.31 ± 0.54, plus 1.06 ± 0.19 AAPs. At 2 weeks, response was observed in 11 patients (35.48%) in the AD group and 18 patients (35.29%) in the AAP augmentation group (χ 2 = 0, p = 1). At week 8, 16 (52.44%) and 27 patients (52.94%) achieved remission (χ 2 = 0, p = 1), respectively. However, baseline HDRS-17 total scores were 18.55 ± 5.73 and 22.39 ± 6.14 (t = 2.819, p < 0.01) for the AD and AAP groups, respectively. Conclusion: Compared with AD treatment, AAP augmentation did not show a more rapid response nor greater remission rates. Considering that the AAP augmentation group had more severe depressive symptoms at baseline, AAP augmentation may be effective in severe MDD.
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Gender differences in sunshine increased antidepressant placebo effect Joël Gailledreau, Béatrice Gailledreau,Nathalie Desbonnet, Philippe Desbonnet Rationale:
Abstract Sunshine increases placebo effect in major depressive disorder (MDD) patients (Gailledreau et al., 2015) . Kokras et al. (2014) showed that sunshine induces different responses in female than male mice in preclinical models of depression. Objective: To determine if the sunshine induced placebo effect exhibits gender differences in human Materiel and Methods: Data from 9 double-blind, randomized, placebo-controlled studies of antidepressants conducted by the French GICIPI network were reviewed. MADRS (5) Although analysis of the females (n=44) demonstrates NS correlation as well for cloudy or variable weather (r 2 =0.0016), there is a strong correlation between sunshine index and Delta MADRS/ Delta HAMD for females exposed to sunny weather: r 2 =0,315, n=20, p<0.01. This correlation is even stronger in the subpopulation of females aged less than 50 years: r 2 =0.6398, n=12, p<0.001. Discussion: The hypothesis underlying this correlation between sunshine index and variations of MADRS/HAMD scales will be discussed. Conclusion: Sunshine increases placebo effect in female patients aged less than 50. This insufficiently known effect may be responsible for failure of a number of double-blind, randomized, studies of antidepressant compounds.
